AnaptysBio Historical Balance Sheet
ANAB Stock | USD 25.12 0.13 0.51% |
Trend analysis of AnaptysBio balance sheet accounts such as Short Long Term Debt Total of 10.8 M, Other Current Liabilities of 30.6 M or Total Current Liabilities of 19.3 M provides information on AnaptysBio's total assets, liabilities, and equity, which is the actual value of AnaptysBio to its prevalent stockholders. By breaking down trends over time using AnaptysBio balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining AnaptysBio latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether AnaptysBio is a good buy for the upcoming year.
AnaptysBio Inventory |
|
AnaptysBio |
About AnaptysBio Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of AnaptysBio at a specified time, usually calculated after every quarter, six months, or one year. AnaptysBio Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of AnaptysBio and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which AnaptysBio currently owns. An asset can also be divided into two categories, current and non-current.
AnaptysBio Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of AnaptysBio assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in AnaptysBio books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on AnaptysBio balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of AnaptysBio are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Liabilities And Stockholders Equity
The total of all liabilities and equity in the company, which should equal the company's total assets according to the accounting equation.Most accounts from AnaptysBio's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into AnaptysBio current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AnaptysBio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.At present, AnaptysBio's Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Property Plant And Equipment Net is expected to grow to about 19.2 M, whereas Total Assets are forecasted to decline to about 354.3 M.
2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 21.0M | 19.5M | 17.8M | 10.8M | Total Assets | 643.1M | 610.4M | 452.4M | 354.3M |
AnaptysBio balance sheet Correlations
Click cells to compare fundamentals
AnaptysBio Account Relationship Matchups
High Positive Relationship
High Negative Relationship
AnaptysBio balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 435.2M | 416.6M | 643.1M | 610.4M | 452.4M | 354.3M | |
Short Long Term Debt Total | 2.2M | 342K | 21.0M | 19.5M | 17.8M | 10.8M | |
Other Current Liab | 871K | 15.3M | 11.3M | 20.0M | 29.2M | 30.6M | |
Total Current Liabilities | 29.5M | 19.8M | 16.1M | 26.1M | 37.4M | 19.3M | |
Total Stockholder Equity | 405.0M | 396.7M | 356.4M | 262.1M | 88.1M | 83.7M | |
Property Plant And Equipment Net | 1.6M | 1.8M | 21.8M | 20.0M | 18.3M | 19.2M | |
Net Debt | (168.8M) | (250.1M) | (474.8M) | (51.9M) | (18.2M) | (19.1M) | |
Retained Earnings | (244.0M) | (264.0M) | (321.8M) | (450.5M) | (614.1M) | (583.4M) | |
Accounts Payable | 16.2M | 4.2M | 1.7M | 2.8M | 4.7M | 4.2M | |
Cash | 171.0M | 250.5M | 495.7M | 71.3M | 36.0M | 34.2M | |
Non Current Assets Total | 57.5M | 20.0M | 89.2M | 163.2M | 45.6M | 53.5M | |
Non Currrent Assets Other | 208K | 1.5M | 662K | 256K | 230.4K | 218.9K | |
Cash And Short Term Investments | 374.2M | 393.7M | 548.1M | 441.2M | 390.9M | 295.2M | |
Common Stock Shares Outstanding | 27.1M | 27.3M | 27.4M | 28.2M | 26.9M | 21.0M | |
Liabilities And Stockholders Equity | 435.2M | 416.6M | 643.1M | 610.4M | 452.4M | 354.3M | |
Non Current Liabilities Total | 654K | 4.6M | 270.5M | 322.2M | 326.8M | 343.2M | |
Other Current Assets | 3.5M | 5.8M | 4.9M | 4.5M | 9.1M | 9.5M | |
Other Stockholder Equity | 213.5M | 660.7M | 678.6M | 717.8M | 703.0M | 738.1M | |
Total Liab | 30.2M | 19.8M | 286.6M | 348.3M | 364.3M | 382.5M | |
Property Plant And Equipment Gross | 1.6M | 1.8M | 21.8M | 20.0M | 24.5M | 25.7M | |
Total Current Assets | 377.7M | 396.6M | 553.9M | 447.2M | 406.8M | 300.8M | |
Accumulated Other Comprehensive Income | 338K | (4K) | (422K) | (5.2M) | (797K) | (836.9K) | |
Short Term Debt | 2.2M | 342K | 3.0M | 3.3M | 3.6M | 2.8M | |
Other Liab | 796K | 654K | 251.1M | 304.4M | 350.1M | 367.6M | |
Net Tangible Assets | 405.0M | 396.7M | 627.0M | 584.3M | 672.0M | 705.6M | |
Other Assets | 208K | 139K | 18.2M | 256K | 294.4K | 279.7K | |
Property Plant Equipment | 3.0M | 1.8M | 2.3M | 2.1M | 2.4M | 1.6M | |
Capital Surpluse | 648.7M | 660.7M | 678.6M | 717.8M | 825.5M | 517.6M | |
Retained Earnings Total Equity | (244.0M) | (264.0M) | (321.8M) | (450.5M) | (405.4M) | (385.2M) | |
Short Term Investments | 203.2M | 143.2M | 52.4M | 369.9M | 354.9M | 252.1M | |
Capital Lease Obligations | 871K | 342K | 21.0M | 19.5M | 17.8M | 9.4M | |
Net Invested Capital | 406.4M | 396.7M | 356.4M | 262.1M | 88.1M | 83.7M | |
Long Term Investments | 54.3M | 17.5M | 67.1M | 142.9M | 27.0M | 25.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether AnaptysBio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AnaptysBio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anaptysbio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anaptysbio Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AnaptysBio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AnaptysBio. If investors know AnaptysBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AnaptysBio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.05) | Revenue Per Share 2.086 | Quarterly Revenue Growth 8.047 | Return On Assets (0.18) | Return On Equity (1.62) |
The market value of AnaptysBio is measured differently than its book value, which is the value of AnaptysBio that is recorded on the company's balance sheet. Investors also form their own opinion of AnaptysBio's value that differs from its market value or its book value, called intrinsic value, which is AnaptysBio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AnaptysBio's market value can be influenced by many factors that don't directly affect AnaptysBio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AnaptysBio's value and its price as these two are different measures arrived at by different means. Investors typically determine if AnaptysBio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AnaptysBio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.